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Background: The association between smoking and asthma or wheeze has been extensively studied in
cross sectional studies, but evidence from large prospective cohort studies on the incidence of asthma
during adolescence is scarce.
Methods: We report data from a cohort study in two German cities, Dresden and Munich. The study
population (n = 2936) was first studied in 1995/6 at age 9–11 years as part of phase II of the International
Study of Asthma and Allergies in Childhood (ISAAC II) and followed up in 2002/3. At baseline the
parents completed a questionnaire and children underwent clinical examination and blood sampling. At
follow up the young adults completed questionnaires on respiratory health, living, and exposure
conditions. Incidence risk ratios (IRR) were calculated and adjusted for potential confounders using a
modified Poisson regression approach.
Results: The adjusted IRR for incident wheeze for active smokers compared with non-smokers was 2.30
(95% confidence interval (CI) 1.88 to 2.82). The adjusted IRR was slightly higher for incident wheeze
without a cold (2.76, 95% CI 1.99 to 3.84) and the incidence of diagnosed asthma (2.56, 95% CI 1.55 to
4.21). Analysis of duration and intensity of active smoking indicated dose dependent associations.
Stratified analyses showed that the risk of incident wheeze without a cold in atopic smokers increased with
decreasing plasma a1-antitrypsin levels at baseline (1.64, 95% CI 1.22 to 2.20 per interquartile range).
Conclusions: Active smoking is an important risk factor for the incidence of asthma during adolescence.
Relatively lower plasma levels of a1-antitrypsin, although well above currently accepted thresholds, may
increase susceptibility to respiratory disease among atopic smokers.
D
eterminants of asthma and wheeze have been exten-
sively studied in cross sectional studies. However, this
study design has a major limitation in its inability to
establish a temporal sequence between exposure and disease.
Evidence from birth cohort studies on risk factors for the
incidence of asthma is currently emerging from several
countries, but most cohorts are still relatively young.
Evidence from cohort studies on risk factors for asthma
incidence during adolescence is scarce.
The results from available cohort studies on the role of
active smoking are conflicting. While some studies observed
an increased incidence of asthma among smokers,1–6 some
found no effect or weak associations,7 8 and one group
reported an inverse relation.9 Only two of these studies
provide data on adolescents.1 6 Exposure to environmental
tobacco smoke (ETS) is also thought to be a risk for the
incidence of respiratory disease. ETS exposure seems to cause
an increase in non-atopic wheezy bronchitis in children
whereas, in children with established asthma, parental
smoking is associated with more severe disease.10 11 In
addition, ETS exposure seems to be a risk factor for chronic
bronchitis and asthma in adults.12 However, longitudinal data
on adolescents are again limited and only one study showed a
significant association between maternal smoking and the
incidence of asthma in their children.11
Apart from the lack of longitudinal data concerning risk
factors for asthma, there is also increasing interest in interac-
tions of environmental exposures with genetic predisposition
and in markers for susceptibility. Attention has recently been
drawn to the harmful effect of glutathione-S-transferase
deficiency and of low plasma a1-antitrypsin levels in combina-
tion with exposure to ETS.13 14 a1-Antitrypsin is a serine protease
inhibitor which primarily binds elastase produced by neutro-
phils during inflammation, preventing elastic tissue like the
lung from degeneration.15
In this paper we present data from a large population based
cohort study in Germany. The study population comprised
2936 children aged 9–11 years at baseline and followed for
about 7 years through adolescence. The objective was to
investigate the role of active and passive smoking on the
incidence of asthma. In addition, we examined differences in
susceptibility to respiratory disease associated with atopy,
smoking, and a1-antitrypsin blood plasma levels.
METHODS
Study population and study design
The baseline population consisted of 9–11 year old partici-
pants in phase II of the International Study of Asthma and
Allergies in Childhood (ISAAC II) in Munich and Dresden in
1995/6.16 Details of the surveys have been described else-
where.17 Briefly, parents of random samples of fourth grade
pupils in Munich (n = 3354, response rate 87.5%) and in
Dresden (n = 3045, response rate 83.0%) responded to a
written questionnaire. Detailed information on respiratory
health, living, and exposure conditions was collected.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; ETS,
environmental tobacco smoke; IRR, incidence risk ratio; SES,
socioeconomic status
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The characteristics of the participants in the follow up
survey (n = 3785) and of the study population included in
the analyses (n = 2936) are shown in fig 1 and table 1. We
excluded 849 participants from the analyses for the following
reasons: (1) Non-German nationality (n = 293). In Germany,
nationality reflects ethnicity rather than place of birth. It is
known that in Germany the prevalence of asthma and
allergies is much higher among children with German
nationality than in those without.18 The proportion of
participants without German nationality differed substan-
tially between the two study centres (Dresden 0.2%, Munich
13.5%). (2) Reported wheeze or asthma during the baseline
survey (n = 494) since this study was on the incidence of
wheeze and asthma. (3) Missing values for wheeze or asthma
at baseline or wheeze at follow up (n = 62).
The studies at baseline were approved by the ethics
committee of the University of Mu¨nster, Germany and the
follow up study was approved by the ethical committees of
the Bavarian Chamber of Physicians and of the Department
of Medicine, Technical University of Dresden.
Questionnaires and clinical examination, blood
sampling and laboratory analysis
The baseline questionnaire consisted of the questionnaire
from the German ISAAC phase II study described in detail
elsewhere.17 The follow up questionnaire consisted mainly of
items from the European Community Respiratory Health
Survey (ECRHS) and ISAAC.16 19 The items in question were
respiratory symptoms and disease as well as allergies among
participants and their families, sociodemographic character-
istics, active and passive smoking, present and previous living
conditions, and several occupational aspects.
At baseline, measurements (n = 2088, 71.1%) of specific
serum IgE antibodies directed against a panel of common
aeroallergens (mixed grass pollen, birch pollen, mugwort
pollen, Dermatophogoides pteronyssinus, cat dander, dog dander,
Cladosporium herbarum) were conducted by fluorescence
enzyme immunoassay (SX1 CAP; Pharmacia, Lund,
Sweden). Skin prick tests (n = 2500, 85.1%) were performed
using extracts of six common aeroallergens (D pteronyssinus, D
farinae, Alternaria tenius, cat hair, mixed tree and mixed grass
pollen). A random subsample underwent spirometric testing
and bronchial challenge using hypertonic saline (n = 1227,
41.8%).14 Plasma levels of a1-antitrypsin were measured in
samples from 2015 children (68.6%) using the rate nephelo-
metric Immuno-Chemistry System (ICS Aray; Beckman
Instruments, Fullerton, CA, USA).16 C-reactive protein
(CRP) levels were measured in plasma (n = 2018, 68.7%) by
standard densiometry (Vitro 250; Johnson & Johnson,
Rochester, NY, USA).
Definitions of variables
Outcome variables
We defined wheeze as either presence of ‘‘wheezing or
whistling in the chest’’ or asthma medication use in the past
12 months. Wheeze without a cold was an affirmative response
to the question ‘‘Have you had this wheezing or whistling
when you did not have a cold?’’. Subjects were defined as
having diagnosed asthma if they had wheeze and reported that a
doctor had either diagnosed ‘‘asthma’’ at least once or
‘‘spastic/asthmatic bronchitis’’ at least twice. Atopy was
assessed only at baseline and defined as either at least one
positive skin reaction (wheal size >3 mm after subtraction of
negative control) to the six tested aeroallergens or specific
serum IgE levels .0.7 kU/l.20
Explanatory variables
Active smoking was determined by responses to ‘‘Have you
ever smoked for as long as a year? (‘‘yes’’ means at least 20
packs of cigarettes in a lifetime, or at least one cigarette per
day or one cigar a week for one year)’’ (yes/no). Age at the
onset of active smoking and age at quitting were reported in
Female sex
German nationality
High socio-economic status
Atopy
Parental history of allergies
Parental history of asthma
Wheeze
α1-antitrypsin 
plasma levels§
For methodological 
reasons** excluded 
participants (n = 849)
Study population: n = 2936
Munich: n = 1480
Dresden: n = 1456
Baseline surveys in 1995/96
Participants: n = 6399
Munich: n = 3354
Dresden: n = 3045
Non-respondents (n = 2614)
45.4%
82.3%
41.6%
36.0%
36.1%
9.2%
9.3%
152.0 (27.5)
No contact agreement: n = 1309
Not located: n = 197
Not participated: n = 1108
Survey at follow up 2002/03
Participants: n = 3785*
Munich: n = 2043
Dresden: n = 1742 
52.4%‡
92.6%‡
53.5%‡
39.9%†
43.9%‡
10.2%
10.5%
152.0 (26.0)
Figure 1 Characteristics of non-respondents (n = 2614) and follow up
participants (n = 3785). % = prevalence. *Participation rate: 77.4% of
those located; p,0.05; `p,0.001; 1median (interquartile range)
mg/dl; **details given in the Methods section.
Table 1 Characteristics of the study population
(n = 2936)
Baseline
n (%)*
Follow up
n (%)*
Mean (SD) age (years) 9.6 (0.56) 17.1 (0.62)
Sex
Female 1592 (54.2) 1592 (54.2)
Male 1344 (45.8) 1344 (45.8)
Symptoms and diagnosis of respiratory disease
Incident wheeze (yes) NA 388 (13.2)
Incident wheeze without a cold (yes) NA 158 (5.8)
Incidence of diagnosed asthma (yes) NA 66 (2.6)
Parental history of
Allergic disease (yes) 1258 (43.2) NA
Asthma (yes) 241 (9.0) NA
Clinical examination
Bronchial hyperreactivity (yes) 186 (15.2) NA
Atopy (yes) 780 (36.6) NA
Median (IQR) plasma a1-antitrypsin (mg/dl) 152.0 (25.0) NA
Active smoking during adolescence (yes) NA 993 (34.1)
Mean (SD) age at onset of smoking (years) NA 14.1 (1.54)
Duration of active smoking
Never NA 1922 (66.4)
(2 years NA 395 (13.6)
2–4 years NA 422 (14.6)
.4 years NA 156 (5.4)
Mean (SD) duration of active smoking (years) NA 2.6 (1.35)
Intensity of active smoking
Never NA 1922 (66.1)
Occasionally NA 169 (5.8)
Daily (10 cigarettes NA 440 (15.1)
Daily .10 cigarettes NA 378 (13.0)
Exposure to ETS (yes) 1094 (38.9) 1863 (63.9)
Exposure to ETS at home (yes) 1094 (38.9) 920 (40.2)
Duration of ETS exposure
Never NA 997 (34.4)
(1 h/day NA 560 (19.3)
1–5 h/day NA 863 (29.8)
.5 h/day NA 478 (16.5)
%, prevalence; SD, standard deviation; IQR, interquartile range; ETS,
environmental tobacco smoke; NA, not applicable/assessed.
*Unless otherwise specified.
Atopy is defined as either at least one positive skin prick test (wheal size
>3 mm after subtraction of negative control) or specific serum IgE levels
.0.7 kU/l (a panel of common aeroallergens tested for both).
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years. Duration of active smoking was calculated as the
difference of the age at onset of smoking and the age at
follow up or, if applicable, the age at quitting. Intensity of
active smoking was obtained by responses to ‘‘How often
have you smoked cigarettes in the last month?’’ and
combined into four categories for analyses (never, occasion-
ally, daily (10 cigarettes, daily .10 cigarettes) to conform to
WHO guidelines and smoking definitions widely used in the
medical literature.
Exposure to ETS was evaluated by the question: ‘‘Does
anybody at present smoke inside your child’s home?’’ (yes/no)
at baseline and by the question: ‘‘Have you been regularly
exposed to tobacco smoke in the last 12 months? (‘‘reg-
ularly’’ means on most days or nights)’’ (yes/no) at follow up.
The duration of ETS exposure at follow up was determined as
reported in hours/day at home, at the workplace, in bars,
restaurants, movie theatres, or similar places, and at other
places. For analyses the sum of all responded hours was
categorised into never, (1 h/day, 1–5 h/day, and .5 h/day.
Putative confounding variables
The following variables were assessed at baseline and tested
as putative confounders in the models: atopy, bronchial
hyperreactivity, sex, study centre, age (at follow up,
continuously), parental history of allergies (at least one
parent reporting a lifetime history of asthma, hayfever, or
atopic dermatitis), parental history of asthma, socioeconomic
status (SES), dampness or mould in the dwelling, exposure
to heavy truck traffic, body mass index (BMI), and ETS
exposure. BMI and ETS exposure at follow up were also
tested as putative confounders. BMI was computed as weight
(kg) divided by the square of height (m2). Cut points for
underweight and overweight were the 10th and 90th
percentiles, respectively, according to the distribution of
BMI among the German population.21 SES was considered
high if either parent had attended school for at least 12 years.
Statistical methods
Participants with missing values were excluded from
analyses involving the respective variable. Three subjects
reported extreme ages at onset of smoking (7 years and
earlier) and were excluded from the analyses of onset and
duration of active smoking. Subjects with plasma CRP levels
higher than 1 mg/dl (sensitivity of laboratory analyses to
detect CRP was 0.6 mg/dl) were regarded to have acute
inflammation and were excluded from the analyses of plasma
a1-antitrypsin levels (n = 48).
Incidence risk ratios (IRR) were estimated using a
modified Poisson regression approach.22 23 The comparison
was always made between incident cases and participants
who never reported the respective outcome. p values from a
x2 test are denoted as px2. Confounding or interaction with
the main exposure variable was tested for the confounding
variables mentioned above. Confounding was defined by
change of >15% in the estimated coefficient of the main
exposure variable by one or joint confounders. Interaction
was presumed if the interaction term was significant with a
p,0.05 and found consistently for the three outcomes. All
multivariate models included sex, age, and study centre
regardless of the confounding effect. Generally, adjustments
did not alter the direction of the observed effect and only
changed statistical significance of estimates in three models;
we therefore do not report crude IRR in the interest of
brevity. Information on the number of cases and non-cases,
however, is given in the tables. All computations were
performed using SAS Software Version 8.02 (SAS Institute
Inc, Cary, NC, USA).
RESULTS
The study population consisted of almost equal numbers in
Dresden and Munich with more females than males (table 1).
At baseline the prevalence of atopy was 36.6% and the
prevalence of bronchial hyperreactivity was 15.2%. About one
third of the subjects were classified as active smokers at
follow up. At baseline, 38.9% experienced exposure to ETS at
home and 40.2% at follow up. Almost 30% reported daily
exposure to ETS of 1–5 hours at follow up.
Table 2 shows the incidence of wheeze and asthma in
relation to active smoking during adolescence. The adjusted
IRR for active smokers compared with non-smokers for
incident wheeze was 2.30 (95% CI 1.88 to 2.82). The adjusted
IRR was higher for more severe outcomes—for example, 2.76
(95% CI 1.99 to 3.84) for incident wheeze without a cold and
2.56 (95% CI 1.55 to 4.21) for the incidence of diagnosed
asthma. The analyses of duration and intensity of active
smoking showed dose dependent associations before and
after adjustment for covariates.
There was a significant interaction between atopy and
active smoking for incident wheeze (p = 0.0016), but not for
incident wheeze without a cold (p = 0.1556) or for incident
asthma (p = 0.9696). Because of the observed interaction and
the potential for a better understanding of the disease
aetiology, we performed the analyses of smoking effects on
wheeze and asthma stratified by atopy (table 3). The pattern
of associations resembled those of the unstratified analysis
Table 2 Incidence (%) of wheeze or asthma between ages 9 and 17 in relation to active smoking during adolescence
Incident wheeze Incident wheeze without a cold Incidence of diagnosed asthma
% (n/N)*
Adjusted IRR
(95% CI) % (n/N)*
Adjusted IRR
(95% CI) % (n/N)*
Adjusted IRR
(95% CI)
Active smoking during adolescence
No 8.4 (160/1907) 3.2 (58/1805) 1.6 (27/1739)
Yes 22.6 (222/983) 2.30 (1.88 to 2.82) 11.4 (98/859) 2.76 (1.99 to 3.84) 4.7 (37/780) 2.56 (1.55 to 4.21)
Duration of active smoking (years)
Never 8.4 (160/1907) 3.2 (58/1805) 1.6 (27/1739)
(2 16.8 (65/388) 1.82 (1.38 to 2.40) 8.0 (28/351) 2.13 (1.37 to 3.33) 2.5 (8/323) 1.43 (0.65 to 3.17)
2–4 24.3 (102/419) 2.45 (1.92 to 3.11) 10.7 (38/355) 2.55 (1.69 to 3.85) 5.7 (19/331) 3.11 (1.71 to 5.65)
.4 31.6 (49/155) 3.10 (2.32 to 4.15) 22.1 (30/136) 4.95 (3.24 to 7.57) 7.3 (8/110) 3.97 (1.84 to 8.57)
Intensity of active smoking
Never 8.4 (160/1907) 3.2 (58/1805) 1.6 (27/1739)
Occasionally 14.3 (24/168) 1.58 (1.06 to 2.36) 7.7 (12/156) 2.13 (1.17 to 3.87) 2.7 (4/146) 1.63 (0.58 to 4.58)
Daily (10 cigs 19.5 (85/435) 2.13 (1.66 to 2.74) 9.3 (36/386) 2.42 (1.61 to 3.64) 4.3 (15/352) 2.46 (1.31 to 4.63)
Daily .10 cigs 29.7 (111/374) 2.95 (2.31 to 3.77) 16.0 (50/313) 3.66 (2.47 to 5.43) 6.5 (18/278) 3.34 (1.80 to 6.19)
n, cases; N, total of exposed; IRR, incidence risk ratio; CI, confidence interval.
*Population comprises subjects without missing values for the outcome, exposure, and confounding variables.
All models adjusted for sex, age, study centre, and duration of exposure to environmental tobacco smoke (ETS) at follow up (for further detail see Methods).
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and most associations were statistically significant. The
estimated IRR tended to be lower for atopic subjects. Table 4
shows the observed associations of ETS exposure with the
incidence of wheeze and asthma for non-smokers. After
adjustment, none of the associations reached statistical
significance.
The relation between decreasing plasma a1-antitrypsin
levels at baseline and the incidence of wheeze and asthma are
shown in fig 2. Plasma levels of a1-antitrypsin ranged from
52.2 mg/dl to 254.0 mg/dl (median 152.0 mg/dl). The IRR
were calculated for a 25 mg/dl decrease in plasma a1-
antitrypsin levels which reflects the interquartile range
(IQR, the difference between the 25th and 75th percentiles)
in the total study population.
In the total cohort, decreasing plasma a1-antitrypsin levels
were not associated with the incidence of wheeze, wheeze
without a cold, and diagnosed asthma. Smoking has been
shown to be an important risk factor for respiratory disease in
subjects with a1-antitrypsin deficiency. Decreasing plasma
levels of a1-antitrypsin carried no statistically significant risk
Table 3 Incidence (%) of wheeze or asthma between ages 9 and 17 in relation to active smoking during adolescence by atopy
at baseline
Incident wheeze Incident wheeze without a cold Incidence of diagnosed asthma
% (n/N)*
Adjusted IRR
(95% CI) % (n/N)*
Adjusted IRR
(95% CI) % (n/N)*
Adjusted IRR
(95% CI)
Atopic subjects
Active smoking during adolescence
No 13.8 (71/515) 6.3 (30/474) 3.4 (15/442)
Yes 25.8 (65/252) 1.63 (1.20 to 2.22) 18.3 (42/229) 2.07 (1.35 to 3.18) 9.7 (19/196) 2.16 (1.15 to 4.06)
Duration of active smoking (years)
Never 13.8 (71/515) 6.3 (30/474) 3.4 (15/442)
(2 18.1 (19/105) 1.18 (0.74 to 1.87) 12.2 (12/98) 1.44 (0.79 to 2.64) 3.5 (3/85) 0.84 (0.26 to 2.69)
2–4 26.7 (27/101) 1.59 (1.08 to 2.34) 17.8 (16/90) 1.86 (1.07 to 3.23) 13.4 (11/82) 2.90 (1.35 to 6.21)
.4 40.5 (15/37) 2.51 (1.58 to 3.99) 35.3 (12/34) 3.87 (2.16 to 6.91) 16.7 (4/24) 3.71 (1.39 to 9.94)
Intensity of active smoking
Never 13.8 (71/515) 6.3 (30/474) 3.4 (15/442)
Occasionally 14.9 (7/47) 1.01 (0.50 to 2.05) 7.0 (3/43) 0.98 (0.33 to 2.89) 2.4 (1/41) 0.64 (0.09 to 4.42)
Daily (10 cigs 23.5 (27/115) 1.55 (1.04 to 2.32) 18.5 (20/108) 2.18 (1.28 to 3.71) 10.1 (9/89) 2.42 (1.11 to 5.27)
Daily .10 cigs 34.8 (31/89) 2.19 (1.48 to 3.23) 24.7 (19/77) 2.63 (1.54 to 4.49) 13.8 (9/65) 3.05 (1.32 to 7.02)
Non-atopic subjects
Active smoking during adolescence
No 5.5 (45/825) 1.9 (15/795) 0.8 (6/778)
Yes 20.8 (104/500) 3.25 (2.22 to 4.76) 9.2 (40/436) 3.92 (2.01 to 7.65) 2.3 (9/399) 2.16 (0.79 to 5.93)
Duration of active smoking (years)
Never 5.5 (45/825) 1.9 (15/795) 0.8 (6/778)
(2 14.2 (26/183) 2.42 (1.48 to 3.98) 6.5 (11/168) 3.13 (1.34 to 7.33) 1.9 (3/158) 1.91 (0.50 to 7.32)
2–4 23.3 (50/215) 3.67 (2.39 to 5.63) 9.3 (17/182) 4.06 (1.90 to 8.68) 2.4 (4/167) 2.27 (0.64 to 8.06)
.4 28.4 (27/95) 4.38 (2.70 to 7.11) 15.0 (12/80) 5.98 (2.68 to 13.35) 2.9 (2/68) 2.84 (0.59 to 13.58)
Intensity of active smoking
Never 5.5 (45/825) 1.9 (15/795) 0.8 (6/778)
Occasionally 14.6 (12/82) 2.46 (1.34 to 4.51) 6.7 (5/75) 3.11 (1.12 to 8.63) 2.9 (2/70) 2.92 (0.61 to 14.03)
Daily (10 cigs 15.8 (35/222) 2.72 (1.73 to 4.30) 5.6 (11/198) 2.68 (1.14 to 6.27) 1.6 (3/187) 1.63 (0.42 to 6.30)
Daily .10 cigs 28.9 (56/194) 4.41 (2.86 to 6.79) 14.8 (24/162) 6.24 (2.94 to 13.22) 2.8 (4/141) 2.42 (0.70 to 8.36)
n, cases; N, total of exposed; IRR, incidence risk ratio; CI, confidence interval.
*Population comprises subjects without missing values for the outcome, exposure, and confounding variables.
All models adjusted for sex, age, study centre, and duration of exposure to environmental tobacco smoke (ETS) at follow up (for further detail see Methods).
Table 4 Incidence of wheeze or asthma between ages 9 and 17 in relation to exposure to environmental tobacco smoke (ETS)
during adolescence for non-smokers
Incident wheeze Incident wheeze without a cold Incidence of diagnosed asthma
% (n/N)*
Adjusted IRR
(95% CI) % (n/N)*
Adjusted IRR
(95% CI) % (n/N)*
Adjusted IRR
(95% CI)
ETS exposure at home at baseline`
No 7.8 (96/1234) 2.8 (33/1171) 1.2 (14/1136)
Yes 9.5 (57/597) 1.22 (0.87 to 1.72) 3.9 (22/562) 1.39 (0.79 to 2.46) 2.2 (12/534) 2.00 (0.84 to 4.76)
ETS exposure at follow up
No 8.0 (71/888) 3.3 (20/599) 1.4 (12/841)
Yes 8.8 (84/952) 1.04 (0.74 to 1.46) 3.7 (25/677) 1.19 (0.68 to 2.10)1 1.7 (15/888) 1.25 (0.57 to 2.73)**
Duration of ETS exposure at follow up (h/day)
Never 8.0 (70/877) 3.0 (25/832) 1.5 (12/809)
(1 7.0 (28/399) 0.88 (0.58 to 1.34) 2.6 (10/381) 0.88 (0.43 to 1.82) 1.4 (5/369) 0.93 (0.33 to 2.64)
1–5 10.5 (48/459) 1.31 (0.92 to 1.86) 4.0 (17/428) 1.35 (0.74 to 2.48) 2.2 (9/406) 1.53 (0.63 to 3.70)
.5 8.1 (14/172) 1.01 (0.58 to 1.77) 3.7 (6/164) 1.24 (0.52 to 2.97) 0.6 (1/155) 0.45 (0.05 to 3.75)
n, cases; N, total of exposed; IRR, incidence risk ratio; CI, confidence interval.
*Population comprises subjects without missing values for the outcome, exposure, and confounding variables.
All models adjusted for sex, age, and study centre (for further detail see Methods).
`Additionally adjusted for duration of ETS exposure at follow up.
Additionally adjusted for ETS exposure at home at baseline.
1Additionally adjusted for atopy.
**Additionally adjusted for intensity of active smoking and duration of active smoking.
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for the incidence of wheeze, wheeze without a cold, and
diagnosed asthma among active smokers. The same was
true for non-smoking subjects exposed to ETS at follow up.
An interaction between active smoking and plasma
a1-antitrypsin levels, which was at least of borderline
statistical significance, was observed only in relation to the
incidence of diagnosed asthma (p = 0.066).
Given the significant interaction between active smoking
and atopy in relation to the incidence of wheeze, we also
explored the effects of a1-antitrypsin stratified by atopy. The
multiplicative interaction between plasma a1-antitrypsin
levels, smoking, and atopic sensitisation had a p value of
0.001 for the incidence of wheeze, p = 0.057 for the incidence
of wheeze without a cold, and p = 0.730 for the incidence of
diagnosed asthma. The estimated relative risks for wheeze
and asthma with decreasing plasma a1-antitrypsin levels are
therefore presented stratified for atopy and smoking status in
fig 2. There was a statistically significant association between
decreasing plasma levels of a1-antitrypsin and the incidence
of wheeze (1.33, 95% CI 1.02 to 1.73) and wheeze without a
cold (1.64, 95% CI 1.22 to 2.20) among atopic smokers. The
incidence of diagnosed asthma was found to be related to
decreasing plasma a1-antitrypsin levels in non-atopic smo-
kers, but the statistical significance was only borderline (1.72,
95% CI 0.96 to 3.06).
DISCUSSION
Our data provide strong evidence that active smoking
increases the incidence of wheeze and asthma during
adolescence. As expected, the increase depended on the
duration and intensity of smoking. The effect of smoking was
stronger in non-atopic than in atopic subjects. There was no
statistically significant association between exposure to ETS
and respiratory outcomes. Our findings suggest that the
incidence of wheeze increases with decreasing plasma levels
of a1-antitrypsin in subjects who were atopic at baseline and
started active smoking during adolescence.
Participation bias is one of the most important biases in
longitudinal studies. In our study 2614 participants of the
baseline survey were classified as non-respondents at follow
up. However, half of them had initially denied further contact
and 197 could not be located for follow up (fig 1). Thus, the
participation rate of those with contact agreement who could
be located was 77.4%, which is reasonable considering the
follow up time of 7 years.
A limitation of our study, as with most epidemiological
studies following childhood through to adolescence, is that
information regarding the child’s health in early life was
reported by the parents whereas information regarding
adolescence is given by the participants themselves.
Subjects with a parental history of allergies were more likely
to participate at follow up. However, there was no significant
association between participation at follow up and parental
history of asthma, which is probably more relevant as a
determinant of the incidence of asthma (fig 1). Wheeze and
diagnosed asthma at ages 9–11 were not associated with the
uptake of smoking during adolescence (IRR 1.04 (95% CI
0.90 to 1.20) and IRR 1.08 (95% CI 0.90 to 1.30),
respectively). Active smoking was assessed at follow up
and, strictly speaking, it cannot be assumed that it preceded
the onset of wheeze or asthma in all cases. Nevertheless,
there was a clear dose-response relationship between dura-
tion or intensity of active smoking and the incidence of
wheeze or asthma. We therefore believe that it is unlikely
that the observed associations are due to reverse causation.
The analyses gave no evidence for differences in the
observed associations between females and males and all
estimates are adjusted for sex. We could not identify a
significant association between exposure to ETS and the
incidence of wheeze or asthma among adolescents. This is in
line with some earlier publications. Nevertheless, data on this
association among adolescents are still limited and the
results so far are conflicting.11
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Figure 2 Incidence risk ratios (IRR) relating the incidence of (A)
wheeze, (B) wheeze without a cold, and (C) diagnosed asthma between
the ages of 9 and 17 years to the plasma level* of a1-antitrypsin at
baseline stratified by atopy at baseline and active smoking during
adolescence. %, incidence; n, cases; N, subjects in category; CI,
confidence interval. *IRR refer to a 25 mg/dl decrease in plasma a1-
antitrypsin levels (that is, the interquartile range in the study population).
The population comprised subjects without missing values for the
outcome, exposure, and confounding variables. `All models were
adjusted for sex, age, and study centre (for further detail see Methods
section).
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The role of active smoking on the incidence of respiratory
disease has been investigated previously. In a study in young
adults (age 17–33 years) Strachan et al4 observed a positive
dose-response relation of both the duration and intensity of
active smoking with the incidence of asthma or wheezing
illness. Larsson1 examined the incidence of asthma in
subjects aged 16–19 years and Withers et al6 studied the
incidence of wheeze between the ages of 7 and 15 years. Both
found a positive association between active smoking and the
incidence of wheeze or asthma. The effects reported by
Larsson were only adjusted for sex. Withers et al did not
report associations with the incidence of diagnosed asthma.
Our study on almost 3000 adolescents goes beyond previous
reports in that it describes the effect of active smoking on the
incidence of wheeze and asthma, taking into account objective
markers of atopic disease and numerous possible confounders.
The comparative epidemiology of atopic and non-atopic
wheeze with regard to different patterns of risk factors has
gained attention.24 25 To contribute to this pivotal distinction,
we have displayed the associations of smoking as well as
plasma a1-antitrypsin levels with the incidence of wheeze
and asthma stratified for atopy. The effect of active smoking
on the incidence of wheeze was stronger in non-atopic
subjects than in atopic subjects. This interaction between
smoking and atopy has been reported previously for the
association of smoking with the prevalence of wheeze,24 with
bronchial responsiveness,26 and with the incidence of asthma
or wheezing illness.4 The proposed explanations include self-
selection of smokers or biological antagonism between atopy
and smoking. In our study, non-atopic subjects took up
smoking more often than atopics (IRR 1.19, 95% CI 1.06 to
1.32). This small effect is, however, unlikely to fully explain
the differences in the stratified analyses. The interaction
between atopy and active smoking did not apply to the
incidence of diagnosed asthma, but it has to be taken into
account that the number of diagnosed asthma cases was
small. The number of participants with diagnosed asthma
might be underestimated owing to mild disease that had not
been recognised. Furthermore, current smoking and ETS
exposure at home were found to be associated with
undiagnosed frequent wheezing among adolescents in the
USA.27 Likewise, in Europe, underdiagnosis of asthma with its
implications on treatment of the disease is still common.28 29
We present new data on the association between plasma
a1-antitrypsin levels and the incidence of wheeze and asthma
stratified by atopy and active smoking. Unlike other studies
we did not investigate a1-antitrypsin deficiency using genetic
alterations but analysed plasma a1-antitrypsin levels inde-
pendently of the genetic background and within the normal
range. To provide a quantification of the observed effects, the
IRR are given for a 25 mg/dl decrease in plasma a1-
antitrypsin levels which reflects the interquartile range
within the study population. The National Heart, Lung and
Blood Institute Registry of a1-antitrypsin deficiency has used
a threshold level that was set by convention to 11 mmol/l
(approximately 60 mg/dl) to identify subjects with a1-
antitrypsin deficiency.30 In our study only one subject had a
plasma a1-antitrypsin level below this threshold and more
than 97% had plasma levels within the normal range of 90–
200 mg/dl.
The effect of a1-antitrypsin deficiency on respiratory
disease has recently been investigated, and a1-antitrypsin
deficiency with its genetic alterations was subject to a review
series in 2004.31 It seems that Z and S alleles, which lead to
low plasma levels of a1-antitrypsin, are associated with an
increased risk of developing lung and liver disease whereas
null variants, with no detectable a1-antitrypsin plasma levels,
may be associated with an increased risk of developing
emphysema.32 However, some data from a national birth
cohort study in Great Britain did show an association
between a1-antitrypsin deficiency and lower respiratory tract
infections in infants, but not impaired respiratory health in
adults.33
In children with genetically determined a1-antitrypsin
deficiency, active smoking seems to be a risk factor for lung
function decline in young adults.15 34 Cross sectional analyses
of our cohort at baseline suggest that children with low levels
of a1-antitrypsin ((116 mg/dl) are at increased risk of
developing pronounced decrements in pulmonary function,
particularly if they are exposed to ETS.14 Further analysis
showed no association between low levels of a1-antitrypsin
and the prevalence of asthma, but suggested an increase in
the vulnerability for lung function decrements among
children with low levels of a1-antitrypsin and asthma.
35
Data on the genetic background of our study population
was assessed at baseline but could not be accessed for the
cohort due to ethical reasons.
Since smoking has been shown to be an important risk
factor for respiratory disease in subjects with a1-antitrypsin
deficiency, we explored a potential interaction between
plasma levels of a1-antitrypsin and smoking for the
respiratory outcomes in our study population. The analyses
of the incidence of diagnosed asthma but not wheeze
suggested an interaction between decreasing a1-antitrypsin
plasma levels and active smoking. It could be speculated that
higher levels of a1-antitrypsin protect active smokers from
respiratory disease by its effects against the degeneration of
elastic tissue during inflammation. In our study, decreasing
plasma a1-antitrypsin levels were associated with the
incidence of wheeze and wheeze without a cold in atopic
smokers and, although only of borderline statistical signifi-
cance, with the incidence of diagnosed asthma in non-atopic
smokers. We have no immediate explanation for this
discrepancy between wheeze and diagnosed asthma. The
relatively small number of cases of diagnosed asthma or
chance may have played a part. The mechanisms by which
smoking, atopy, and a1-antitrypsin may interact during
chronic inflammation of the lung are not fully understood.
To our knowledge, this is the first study to report a relation
between relatively lower plasma a1-antitrypsin levels within
the normal range, in combination with smoking and atopy,
and the incidence of wheeze and asthma. If our results are
confirmed, children with low plasma a1-antitrypsin levels
may be a target group for smoking prevention programmes.
In conclusion, our data indicate that active smoking is an
important risk factor for the incidence of wheeze and asthma
during adolescence. The relative risk increases with the
duration and intensity of active smoking and seems to be
higher in non-atopic than in atopic subjects. Relatively lower
plasma levels of a1-antitrypsin, although well above currently
accepted thresholds, may increase susceptibility to respiratory
disease among atopic smokers.
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